Antisense Oligonucleotide (Aso) Therapy In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antisense oligonucleotide (ASO) therapy represents a promising RNA-targeting approach for neurodegenerative diseases. ASOs are short, synthetic single-stranded DNA sequences designed to selectively bind to target messenger RNA (mRNA) or pre-mRNA, modulating protein expression through various mechanisms.
ASOs exert their therapeutic effects through several molecular mechanisms:
- ASOs form DNA-RNA hybrids with target mRNA
- RNase H recognizes and cleaves the RNA strand
- Leads to degradation of the target mRNA
- Reduces translation of the corresponding protein
- ASOs bind to regulatory regions (splice sites, IRES, miRNA binding sites)
- Block translation initiation or splicing
- Do not require RNase H activity
- Useful for modulating splicing patterns
- Double-stranded siRNAs trigger RNAi pathway
- Guide RISC complex to target mRNA
- Leads to sequence-specific mRNA cleavage
flowchart TD
A[ASO Administration] --> B[Systemic Delivery] -->
B --> C[Cross Blood-Brain Barrier] -->
C --> D[Neuronal Uptake] -->
D --> E{RNA Target Type}
E -->|Pre-mRNA| F[Splice Modulation] -->
E -->|mRNA| G[RNase H Degradation] -->
E -->|miRNA| H[miRNA Inhibition] -->
F --> I[Alternative Splicing] -->
G --> J[Reduced Protein Expression] -->
H --> K[ Derepressed Target mRNA] -->
I --> L[Therapeutic Effect] -->
J --> L
K --> L
¶ ASO Chemistry and Delivery
| Modification |
Purpose |
Example |
| Phosphorothioate |
nuclease resistance, RNase H activation |
First-generation ASOs |
| 2'-O-methyl |
stability, binding affinity |
Second-generation |
| 2'-O-methoxyethyl |
improved stability, reduced toxicity |
Second-generation |
| Locked nucleic acid (LNA) |
high binding affinity, nuclease resistance |
Third-generation |
| Peptide nucleic acid (PNA) |
high stability, sequence specificity |
Third-generation |
| Morpholino |
stable, no RNase H activation |
Third-generation |
- Intrathecal Administration: Direct delivery to cerebrospinal fluid
- Conjugate Approaches: ASO-antibody or ASO-lipid conjugates
- Exosome Delivery: Engineered exosomes for targeted CNS delivery
- AAV Vectors: For long-term expression of short hairpin RNAs
- BIIB080 (tau ASO): Targeting MAPT mRNA to reduce tau protein
- IONIS-MAPT Rx: Completed Phase 1/2 trials showing dose-dependent tau reduction
- APOE ASOs: Targeting APOE4 expression
- ASO targeting LRRK2: Reducing mutant LRRK2 kinase activity
- ASO targeting GBA: Modulating glucocerebrosidase expression
- α-Synuclein ASOs: Reducing synuclein aggregation
- BIIB067 (tofersen): Targeting SOD1 mutations - FDA approved
- ASO targeting C9orf72: Reducing toxic dipeptide repeat proteins
- ATXN2 ASOs: For SALS2-linked ALS
- Tominersen (RG6042): Targeting mutant huntingtin - Phase 3 trials
- IONIS-HTTRx: First ASO to lower huntingtin protein in humans
| Advantage |
Description |
| High Specificity |
Single nucleotide discrimination possible |
| Broad Target Range |
Any gene with known sequence |
| Reversible Effects |
Can停止 treatment if needed |
| Disease-Modifying |
Targets root cause rather than symptoms |
¶ Challenges and Limitations
- Delivery: Efficient BBB crossing remains challenging
- Off-Target Effects: Unintended hybridization can cause toxicity
- Immunogenicity: ASO or conjugate components may trigger immune response
- Duration: Repeat dosing may be required
- Cost: Manufacturing complex modified ASOs is expensive
| Drug |
Target |
Disease |
Phase |
Status |
| Tominersen |
HTT |
HD |
Phase 3 |
Discontinued |
| BIIB067 |
SOD1 |
ALS |
Approved |
Completed |
| BIIB080 |
MAPT |
AD |
Phase 1/2 |
Completed |
| IONIS-MAPT |
MAPT |
AD |
Phase 1/2 |
Completed |
| ASO-GRB2-SNAP |
GRB2 |
PD |
Preclinical |
Development |
- Allele-Selective ASOs: Targeting mutant alleles while sparing wild-type
- Splice-Switching ASOs: Correcting aberrant splicing patterns
- Combination Therapy: ASOs with small molecules or biologics
- Gene Editing Integration: CRISPR-based approaches as next generation
The study of Antisense Oligonucleotide (Aso) Therapy In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bennett CF, et al. (2019). "Therapeutic Antisense Oligonucleotides Are Coming of Age." Annual Review of Medicine. 70:307-321.
- Kordasner MH, et al. (2022). "Antisense Oligonucleotide Therapies for Neurodegenerative Diseases." Annual Review of Neuroscience. 45:379-404.
- Smith RA, et al. (2021). "Antisense Oligonucleotide Therapeutics for ALS." Brain Research. 1758:147283.
- Zhou Y, et al. (2023). "ASO Therapy in Alzheimer's Disease: Current Status and Future Directions." Journal of Neurochemistry. 164:23-45.
- Tabrizi SJ, et al. (2019). "Targeting Huntingtin Protein in Huntington's Disease." New England Journal of Medicine. 381:488-491.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
5 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 32%